X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad

By Ernest Kawka  |    April 29, 2022
More than two years into the COVID-19 pandemic, the world has witnessed the immense value of biopharmaceutical innovation. With numerous safe and effective vaccines and treatments developed in record...   Read More

PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework

By Douglas Petersen  |    April 13, 2022
Last fall, President Biden announced that the United States would explore development of an Indo-Pacific Economic Framework (IPEF) to deepen economic relations in the region and collaborate to...   Read More

Research and development continues long after a medicine is initially approved

By Jocelyn Ulrich  |    February 1, 2022
The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...   Read More

Protecting U.S. innovation abroad to support economic and pandemic recovery

By Ernest Kawka  |    February 1, 2022
PhRMA’s recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2022 Special 301 Report reinforce how the United States can confirm its strong commitment to defend...   Read More

Legislation threatens patent protections and future innovation

By Tom Wilbur  |    January 12, 2022
Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant more...   Read More

Global COVID-19 vaccination matters now and for the future

By Anne McDonald Pritchett, PhD  |    November 29, 2021
Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more...   Read More

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

By Tim McClung  |    November 1, 2021
A new report from NDP Analytics showcases how innovation is the lifeblood of economic growth in the United States and that intellectual property (IP) protections are a crucial driver for high rates...   Read More

PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19 and other diseases

By Douglas Petersen  |    October 29, 2021
The biopharmaceutical industry has been working tirelessly to develop and manufacture innovative vaccines, therapies and diagnostics to combat COVID-19 and other diseases and illnesses. As of October...   Read More

Patients and innovators lose if the government pursues ‘march-in’

By Megan Van Etten  |    September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...   Read More

Supporting country readiness to boost global vaccine access

By Megan Van Etten  |    August 12, 2021
The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates